ArticlePediatric nephrology (Berlin, Germany)2015
Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome.
Article in Pediatric nephrology (Berlin, Germany), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.International journal of clinical oncology · 2023Guideline
- Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.Medicine · 2018Trial
- Emerging Immune Cell Biomarkers in Primary Membranous Nephropathy: Immune Cell Profiling During Anti-CD20 B Cell-Targeted Therapy.International journal of molecular sciences · 2026Review
- Mosunetuzumab for relapsed follicular lymphoma presenting with chylothorax: A case report and literature review.Journal of clinical and experimental hematopathology : JCEH · 2026Review
- Successful Therapy with Obinutuzumab in a Toddler with Primary Multidrug-Resistant Nephrotic Syndrome.Journal of clinical medicine · 2025Article
- Pharmacokinetic Characterization of Rituximab in Patients with Glomerular Diseases.Therapeutic drug monitoring · 2025Article
- Patient background and laboratory variables associated with the efficacy of nivolumab after chemoradiotherapy in esophageal squamous cell carcinoma.Molecular and clinical oncology · 2025Article
- Long-term efficacy of Rituximab in steroid dependent and frequent relapsing adult nephrotic syndrome.BMC nephrology · 2025Article
- Low serum concentrations of bevacizumab and nivolumab owing to excessive urinary loss in patients with proteinuria: a case series.Cancer chemotherapy and pharmacology · 2024Article
- Efficacy and safety of long-term repeated use of rituximab in pediatric patients with nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2024Article
- Therapeutic drug monitoring in childhood idiopathic nephrotic syndrome: a state of the art review.Pediatric nephrology (Berlin, Germany) · 2024Review
- Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives.Frontiers in immunology · 2022Review
- Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?Journal of clinical medicine · 2021Review
- Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review.Clinical kidney journal · 2021Review
- Effective cholesterol lowering after myocardial infarction in patients with nephrotic syndrome may require a multi-pharmacological approach: a case report.European heart journal. Case reports · 2021Article
- Population Pharmacokinetics of Rituximab in Pediatric Patients With Frequent-Relapsing or Steroid-Dependent Nephrotic Syndrome.Frontiers in pharmacology · 2021Article
- Rituximab experience in children with nephrotic syndrome: what have we observed differently.Turk pediatri arsivi · 2020Article
- Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.Pediatric nephrology (Berlin, Germany) · 2020Review
- Understanding Inter-Individual Variability in Monoclonal Antibody Disposition.Antibodies (Basel, Switzerland) · 2019Review
- Concentration and Glycoform of Rituximab in Plasma of Patients with B Cell Non-Hodgkin's Lymphoma.Pharmaceutical research · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRituximab (RTX) has recently been introduced as a second-line therapy for nephrotic syndrome in children. Studies show that RTX given during the nephrotic state may be less effective than treatment during a non-nephrotic state, possibly due to loss of RTX in the urine. CASE-DIAGNOSIS/TREATMENT: We describe a 10-year-old boy with steroid-resistant nephrotic syndrome (SRNS) treated with RTX during a phase of active non-selective proteinuria. The serum half-life of RTX in this patient was less than 1 day compared to 20 days in patients without protein losses. Urinary clearance was at least 25 %, compared to approximately 0 % in control patients. However, RTX loss in the urine, as well as in pleural effusion and ascites, only partly explains the rapid drop in the serum RTX concentration of this patient.
conclusionsSerum half-life of RTX can be extremely short, partly due to excessive urinary losses in therapy-resistant nephrotic syndrome with non-selective proteinuria, as seen in our patient. These findings may help to explain the poor results of RTX treatment in patients with active proteinuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.